Kim E, et al. - Researchers assessed the expression of SLC2A (Solute carrier 2A) genes in colorectal cancer and also determined how these were related to prognosis. For this purpose, they used data acquired from the TCGA (the cancer genome atlas) for the discovery sample which included 345 patients, and a dataset from the Gene Expression Omnibus for the validation sample which comprised 501 patients. In both the discovery sample and validation sample, a significant association of SLC2A3 with overall survival (OS) and disease-free survival (DFS) was found. Based on the findings, they concluded that in colorectal cancer patients, there is a link between upregulation of the SLC2A3 genes and decreased OS and DFS. Therefore, SLC2A3 gene expression assessment could have utility for predicting prognosis in these patients.